Drug Interactions between Mavenclad and modafinil
This report displays the potential drug interactions for the following 2 drugs:
- Mavenclad (cladribine)
- modafinil
Interactions between your drugs
No interactions were found between Mavenclad and modafinil. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Mavenclad
A total of 499 drugs are known to interact with Mavenclad.
- Mavenclad is in the drug class antimetabolites.
- Mavenclad is used to treat Multiple Sclerosis.
modafinil
A total of 521 drugs are known to interact with modafinil.
- Modafinil is in the drug class CNS stimulants.
-
Modafinil is used to treat the following conditions:
- ADHD (off-label)
- Chronic Fatigue Syndrome (off-label)
- Depression (off-label)
- Fatigue (off-label)
- Idiopathic Hypersomnia (off-label)
- Narcolepsy
- Obstructive Sleep Apnea/Hypopnea Syndrome
- Shift Work Sleep Disorder
Drug and food interactions
cladribine food
Applies to: Mavenclad (cladribine)
ADJUST DOSING INTERVAL: Oral cladribine may increase the bioavailability of other drugs, which may increase the risk or severity of adverse reactions. Cladribine tablets may contain hydroxypropyl betadex, which could form a complex with the active ingredients of other drugs, especially agents with low solubility. The clinical relevance of this interaction remains unknown.
MANAGEMENT: Administration of oral cladribine should be separated from any other oral drug by at least 3 hours.
References (3)
- (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
modafinil food
Applies to: modafinil
Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability. According to the product labeling, modafinil's absorption may be delayed by approximately one hour if taken with food. Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.
References (2)
- (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
- (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.